MX2018009881A - Modulacion de hipoxia asociada a accidente cerebrovascular. - Google Patents
Modulacion de hipoxia asociada a accidente cerebrovascular.Info
- Publication number
- MX2018009881A MX2018009881A MX2018009881A MX2018009881A MX2018009881A MX 2018009881 A MX2018009881 A MX 2018009881A MX 2018009881 A MX2018009881 A MX 2018009881A MX 2018009881 A MX2018009881 A MX 2018009881A MX 2018009881 A MX2018009881 A MX 2018009881A
- Authority
- MX
- Mexico
- Prior art keywords
- stroke
- nox
- modulation
- oxygen
- hypoxia associated
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title abstract 5
- 230000007954 hypoxia Effects 0.000 title abstract 2
- 230000001146 hypoxic effect Effects 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/06—Processes for producing mutations, e.g. treatment with chemicals or with radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01247—Codeinone reductase (NADPH) (1.1.1.247)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01059—Protein geranylgeranyltransferase type I (2.5.1.59)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Nutrition Science (AREA)
Abstract
La invención proporciona proteínas H-NOX para el suministro de oxígeno a tejido hipóxico después de accidente cerebrovascular. Las proteínas H-NOX se extravasan en la penumbra hipóxica asociada con el accidente cerebrovascular y se acumulan preferentemente para el suministro sostenido de oxígeno al tejido hipóxico para mejorar los efectos adversos de la hipoxia relacionada con el accidente cerebrovascular. En algunas modalidades, las proteínas H-NOX comprenden H-NOX PEGiladas y H-NOX no PEGiladas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662296009P | 2016-02-16 | 2016-02-16 | |
PCT/US2017/018233 WO2017143104A1 (en) | 2016-02-16 | 2017-02-16 | Modulation hypoxia associated with stroke |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009881A true MX2018009881A (es) | 2019-01-31 |
Family
ID=58191670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009881A MX2018009881A (es) | 2016-02-16 | 2017-02-16 | Modulacion de hipoxia asociada a accidente cerebrovascular. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20200276265A1 (es) |
EP (1) | EP3416673B1 (es) |
JP (1) | JP2019511567A (es) |
KR (1) | KR20180123034A (es) |
CN (1) | CN109069582A (es) |
AU (1) | AU2017219869A1 (es) |
BR (1) | BR112018016829A2 (es) |
CA (1) | CA3014651A1 (es) |
DK (1) | DK3416673T3 (es) |
ES (1) | ES2939181T3 (es) |
IL (1) | IL261178A (es) |
MX (1) | MX2018009881A (es) |
RU (1) | RU2018131359A (es) |
SG (2) | SG11201806920SA (es) |
WO (1) | WO2017143104A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2897018C (en) * | 2013-01-07 | 2021-07-27 | Omniox, Inc. | Polymeric forms of h-nox proteins |
WO2020037052A1 (en) | 2018-08-15 | 2020-02-20 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
EP1011710B1 (en) | 1997-02-28 | 2005-08-17 | The Regents of the University of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
WO2003049760A1 (en) * | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
EP2032156B1 (en) | 2006-05-22 | 2012-11-21 | The Regents of the University of California | Compositions and methods for the delivery of oxygen |
CA2897018C (en) | 2013-01-07 | 2021-07-27 | Omniox, Inc. | Polymeric forms of h-nox proteins |
-
2017
- 2017-02-16 MX MX2018009881A patent/MX2018009881A/es unknown
- 2017-02-16 SG SG11201806920SA patent/SG11201806920SA/en unknown
- 2017-02-16 ES ES17708103T patent/ES2939181T3/es active Active
- 2017-02-16 BR BR112018016829A patent/BR112018016829A2/pt not_active IP Right Cessation
- 2017-02-16 CN CN201780023823.8A patent/CN109069582A/zh active Pending
- 2017-02-16 CA CA3014651A patent/CA3014651A1/en not_active Abandoned
- 2017-02-16 JP JP2018561933A patent/JP2019511567A/ja active Pending
- 2017-02-16 SG SG10202007517TA patent/SG10202007517TA/en unknown
- 2017-02-16 WO PCT/US2017/018233 patent/WO2017143104A1/en active Application Filing
- 2017-02-16 US US15/998,557 patent/US20200276265A1/en not_active Abandoned
- 2017-02-16 RU RU2018131359A patent/RU2018131359A/ru not_active Application Discontinuation
- 2017-02-16 KR KR1020187026176A patent/KR20180123034A/ko unknown
- 2017-02-16 EP EP17708103.1A patent/EP3416673B1/en active Active
- 2017-02-16 AU AU2017219869A patent/AU2017219869A1/en not_active Abandoned
- 2017-02-16 DK DK17708103.1T patent/DK3416673T3/da active
-
2018
- 2018-08-15 IL IL261178A patent/IL261178A/en unknown
-
2020
- 2020-12-23 US US17/133,180 patent/US20210121521A1/en not_active Abandoned
-
2023
- 2023-04-27 US US18/308,203 patent/US20240026399A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210121521A1 (en) | 2021-04-29 |
CN109069582A (zh) | 2018-12-21 |
RU2018131359A (ru) | 2020-03-17 |
BR112018016829A2 (pt) | 2018-12-26 |
RU2018131359A3 (es) | 2020-08-12 |
KR20180123034A (ko) | 2018-11-14 |
US20240026399A1 (en) | 2024-01-25 |
SG10202007517TA (en) | 2020-09-29 |
EP3416673B1 (en) | 2022-11-02 |
JP2019511567A (ja) | 2019-04-25 |
CA3014651A1 (en) | 2017-08-24 |
IL261178A (en) | 2018-10-31 |
SG11201806920SA (en) | 2018-09-27 |
US20200276265A1 (en) | 2020-09-03 |
WO2017143104A8 (en) | 2018-09-07 |
ES2939181T3 (es) | 2023-04-19 |
AU2017219869A1 (en) | 2018-08-30 |
WO2017143104A1 (en) | 2017-08-24 |
EP3416673A1 (en) | 2018-12-26 |
DK3416673T3 (da) | 2023-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
NZ709825A (en) | Polymeric forms of h-nox proteins | |
EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
MX347703B (es) | Co-agonistas del receptor de glucagon/glp-1. | |
BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
PH12014502537A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
MX2024008826A (es) | Composicion para la estimulacion ovarica controlada. | |
MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
WO2018053180A3 (en) | Proximity-based sortase-mediated protein purification and ligation | |
MX2019013210A (es) | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. | |
EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
EA201891138A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
MY194351A (en) | Recombinant Human-Basic Fibroblast Growth Factor (Rh-Bfgf) and Pharmaceutical Composition Comprising Rh-Bfgf | |
SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
MX2018009881A (es) | Modulacion de hipoxia asociada a accidente cerebrovascular. | |
MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
TN2014000391A1 (en) | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours | |
UA91739U (uk) | Спосіб лікування безбольової ішемії міокарда у хворих на артеріальну гіпертензію | |
UA100197U (en) | METHOD FOR PREVENTING FERRUM DEFICIENCY ANEMIA | |
TN2013000524A1 (en) | Glucagon/glp-1 receptor co-agonists | |
RU2011150912A (ru) | Арбалет с полым луком |